SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Edwards Lifesciences' transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

Newswise — The University of Michigan Frankel Cardiovascular Center has performed its 300th procedure to fix heart valves using tiny tubes threaded through blood vessels. The procedure, called ...

Edwards Lifesciences (NYSE:EW) benefits from expanded Medicare coverage for TAVR and a structural heart deal, keeping the healthcare device maker in focus.

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

In cardiovascular medicine, the most disruptive "product" of the past decade hasn’t been an app or a wearable. It’s a family of catheter-based heart valves and monitoring systems from Edwards ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...